Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction

Vanhoutte D, Schellings MWM, Gotte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortes V, Rigotti A, Stepp MA, Van de Werf F, Carmeliet P, Pinto YM, Heymans S

Forschungsartikel (Zeitschrift)

Zusammenfassung

Background - The cell- associated proteoglycan syndecan-1 ( Synd1) closely regulates inflammation and cell- matrix interactions during wound healing and tumorigenesis. The present study investigated whether Synd1 may also regulate cardiac inflammation, matrix remodeling, and function after myocardial infarction ( MI). Methods and Results - First, we showed increased protein and mRNA expression of Synd1 from 24 hours on, reaching its maximum at 7 days after MI and declining thereafter. Targeted deletion of Synd1 resulted in increased inflammation and accelerated, yet functionally adverse, infarct healing after MI. In concordance, adenoviral gene expression of Synd1 protected against exaggerated inflammation after MI, mainly by reducing transendothelial adhesion and migration of leukocytes, as shown in vitro. Increased inflammation in the absence of Synd1 resulted in increased monocyte chemoattractant protein-1 expression, increased activity of matrix metalloproteinase- 2 and - 9, and decreased activity of tissue transglutaminase, associated with increased collagen fragmentation and disorganization. Exaggerated inflammation and adverse matrix remodeling in the absence of Synd1 increased cardiac dilatation and impaired systolic function, whereas gene overexpression of Synd1 reduced inflammation and protected against cardiac dilatation and failure. Conclusions - Increased expression of Synd1 in the infarct protects against exaggerated inflammation and adverse infarct healing, thereby reducing cardiac dilatation and dysfunction after MI in mice.

Details zur Publikation

FachzeitschriftCirculation
Jahrgang / Bandnr. / Volume115
Ausgabe / Heftnr. / Issue4
Seitenbereich475-482
StatusVeröffentlicht
Veröffentlichungsjahr2007 (30.01.2007)
Sprache, in der die Publikation verfasst istEnglisch
DOI10.1161/CIRCULATIONAHA.106.644609
Stichwörtergene therapy heart failure inflammation myocardial infarction remodeling leukocyte-endothelial interactions collagen cross-linking heparan-sulfate targeted deletion mice inhibition failure inflammation adhesive rupture

Autor*innen der Universität Münster

Götte, Martin
Klinik für Frauenheilkunde und Geburtshilfe
Vestweber, Dietmar
Max-Planck-Institut für Molekulare Biomedizin

Projekte, aus denen die Publikation entstanden ist

Laufzeit: 01.01.2010 - 31.12.2012
Gefördert durch: Deutsch-Israelische Stiftung für Wissenschaftliche Forschung und Entwicklung
Art des Projekts: Gefördertes Einzelprojekt

Habilitationen, aus denen die Publikation resultiert

Rolle des Heparansulfatproteoglykans Syndecan-1 als Modulator von Entzündungsvorgängen und Tumorprogression
Habilitand*in: Götte, Martin | Gutachter*innen: Kiesel, Ludwig
Zeitraum: 01.01.2008 - 12.04.2011
Habilitationsverfahren erfolgt(e) an: Habilitationsverfahren erfolgt(e) an der Universität Münster